Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis
Maika Durantez1, Catherine Fayolle, Noelia Casares
1University of Navarra, Centre for Applied Medical Research (CIMA), Gene Therapy and Hepatology Area, Pamplona 31008, Spain.
Abstract:
Staphylococcus epidermidis releases a complex of at least four peptides, termed phenol-soluble modulins (PSM), which stimulate macrophages to produce proinflammatory cytokines via activation of TLR2 signalling pathway. We demonstrated that covalent linkage of PSM peptides to an antigen facilitate its capture by dendritic cells and, in combination with different TLR ligands, can favour the in vivo induction of strong and persistent antigen-specific immune responses. Treatment of mice grafted with HPV16-E7-expressing tumor cells (TC-1) with poly(I:C) and a peptide containing αMod linked to the H-2D(b)-restricted cytotoxic T-cell epitope E7(49-57) from HPV16-E7 protein allowed complete tumor regression in 100% of the animals. Surprisingly, this immunomodulatory property of modulin-derived peptides was TLR2 independent and partially dependent upon the EGF-receptor signalling pathway. Our results suggest that alpha or gamma modulin peptides may serve as a suitable antigen carrier for the development of anti-tumoral or anti-viral vaccines.
Insights
Phenol-soluble modulin (PSM) peptides from Staphylococcus epidermidis can be engineered as vaccine carriers. Linking PSMs to antigens enhances immune responses, leading to complete tumor regression in mice.
Area of Science:
- Immunology
- Microbiology
- Vaccine Development
Background:
- Staphylococcus epidermidis releases phenol-soluble modulin (PSM) peptides.
- PSMs activate macrophages and the TLR2 signaling pathway, inducing proinflammatory cytokines.
- Antigen presentation by dendritic cells is crucial for adaptive immunity.
Purpose of the Study:
- To investigate the potential of PSM peptides as antigen carriers for vaccine development.
- To evaluate the efficacy of PSM-antigen conjugates in inducing antigen-specific immune responses.
- To explore the underlying mechanisms of PSM-mediated immunomodulation.
Main Methods:
- Covalent linkage of PSM peptides to model antigens.
- In vivo studies using a mouse tumor model (TC-1 cells).
- Administration of poly(I:C) and PSM-antigen conjugates.
- Analysis of tumor regression and immune responses.
Main Results:
- PSM-antigen conjugates facilitated antigen capture by dendritic cells.
- Treatment resulted in complete tumor regression in 100% of treated mice.
- Immunomodulatory effects were independent of TLR2 but partially dependent on EGF-receptor signaling.
Conclusions:
- Alpha or gamma modulin peptides show promise as antigen carriers for vaccines.
- PSM-based vaccines could be effective against tumors and viral infections.
- The findings suggest novel strategies for vaccine design leveraging bacterial peptides.
